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Abstract
Background: In the acute phase of infection with feline immunodeficiency virus (FIV), the virus targets activated CD4+ 
T cells by utilising CD134 (OX40) as a primary attachment receptor and CXCR4 as a co-receptor. The nature of the virus-
receptor interaction varies between isolates; strains such as GL8 and CPGammer recognise a "complex" determinant 
on CD134 formed by cysteine-rich domains (CRDs) 1 and 2 of the molecule while strains such as PPR and B2542 require 
a more "simple" determinant comprising CRD1 only for infection. These differences in receptor recognition manifest as 
variations in sensitivity to receptor antagonists. In this study, we ask whether the nature of the virus-receptor 
interaction evolves in vivo.
Results: Following infection with a homogeneous viral population derived from a pathogenic molecular clone, a 
quasispecies emerged comprising variants with distinct sensitivities to neutralising antibody and displaying evidence 
of conversion from a "complex" to a "simple" interaction with CD134. Escape from neutralising antibody was mediated 
primarily by length and sequence polymorphisms in the V5 region of Env, and these alterations in V5 modulated the 
virus-receptor interaction as indicated by altered sensitivities to antagonism by both anti-CD134 antibody and soluble 
CD134.
Conclusions: The FIV-receptor interaction evolves under the selective pressure of the host humoral immune response, 
and the V5 loop contributes to the virus-receptor interaction. Our data are consistent with a model whereby viruses 
with distinct biological properties are present in early versus late infection and with a shift from a "complex" to a 
"simple" interaction with CD134 with time post-infection.
Background
Infection with feline immunodeficiency virus (FIV)
results in a progressive immune-dysfunction character-
ized by a gradual decline in helper (CD4+) T lympho-
cytes. Clinical signs include non-resolving gingivitis-
stomatitis, wasting, cachexia, neuropathological deficits,
and an increased incidence of malignancy [1-9]. In the
United Kingdom alone there are approximately 10 million
domestic cats[10] with a seroprevalence approaching
5%[6], this equates to approximately 0.5 million FIV-
infected cats. Given the similarities between the clinical
outcomes of infection with FIV and the human immuno-
deficiency virus (HIV), FIV infection of the domestic cat
is established as a valuable non-primate model for AIDS
in humans, providing insights into the likely efficacy of
potential vaccine strategies and facilitating the explora-
tion of novel therapeutic interventions[11,12]. The pri-
mate lentiviruses use CD4 as a primary receptor [13-15],
and the restricted expression of CD4 in vivo targets the
virus preferentially to T-helper (Th) lymphocytes and
cells of the monocyte/macrophage lineage. However,
CD4-expression alone is insufficient to confer suscepti-
bility to infection with HIV, which also requires co-recep-
tors, principally the chemokine receptors CXCR4 and
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Page 2 of 13CCR5 [16-19](reviewed in [20]). In HIV infection, disease
progression is often accompanied by a shift in the co-
receptor usage of the dominant variants in the peripheral
circulation, from CCR5 (and occasionally CCR3)-depen-
dent to CXCR4-dependent viruses [21-25](reviewed in
[26]). In contrast to the primate lentiviruses, all primary
isolates of FIV isolated from domestic cats tested to date
utilise CD134 (OX40) as a primary attachment receptor
[27-29] and CXCR4 as a co-receptor [30-34] (CCR5 does
not mediate infection with FIV[35]). Recent data have
revealed two distinct modes of interaction between FIV
and its primary receptor CD134 (reviewed in[36]). FIV
strains such as GL8 and CPG require determinants in
both CRD1 and CRD2 of CD134 for infection while at the
other extreme, B2542 and PPR are capable of infecting via
an interaction with CRD1 alone[27,37]. Preliminary anal-
yses of the modes of CD134 interaction of diverse strains
of FIV have indicated that GL8 and B2542 represent two
extremes of a spectrum, with many viruses displaying an
intermediate dependency on determinants within CRD2
for infection [27,36]. As yet there are no data to discern
whether differences in the nature of the Env-CD134
interaction contribute to pathogenicity in vivo; however,
there is a correlation between the nature of the Env-
CD134 interaction and sensitivity to antagonism by solu-
ble CD134L and anti-CD134[38,39].
Previously, we proposed that early infection with FIV
may be dominated by viruses with a complex, high affin-
ity interaction with CD134 (reviewed in [36,40]) and
which target cells where CD134 is abundant (activated
CD4+ T cells[29]) and which have a restricted cell tro-
pism. With disease progression, variants would emerge
that have a less complex, low affinity interaction with
CD134 and a propensity for CD134-independent infec-
tion through a direct interaction with CXCR4. Accord-
ingly the cell tropism of the virus may shift with disease
progression leading to viral dissemination into novel cel-
lular compartments. These variants may be controlled by
the humoral immune response in early infection, but
would become more abundant as the disease progressed
through escape from neutralisation and exhaustion of the
humoral immune response. In this study we examined
the diversity of viral variants in the blood of a cat infected
with a molecular clone of FIV strain GL8 (GL8414). As a
first step towards understanding the process of viral evo-
lution in FIV infection, we characterised the biological
properties of the viral variants from this animal and dem-
onstrated the emergence of variants with distinct recep-
tor usages and sensitivities to neutralising antibodies.
Moreover, we demonstrate for the first time that muta-
tions in the V5 loop, a primary target for escape from
neutralisation may modulate the virus-receptor interac-
tion, suggesting that escape from neutralising antibodies
may drive alterations in the virus-receptor interaction.
Methods
Preparation of genomic DNAs
Peripheral blood mononuclear cells (PBMC) were col-
lected at post mortem (p.m.) from a cat (A613) infected
for 322 weeks with the 414 molecular clone of FIV-
GL8[41]. A613 was one of a group of 3 specific pathogen-
free cats infected with the 414 clone. Following infection,
the virus achieved a high proviral load in PBMC and trig-
gered a depletion of CD4+ lymphocytes and the expan-
sion of an activated CD8+ lymphocytes subset [41].
Retrospective analysis of PBMCs collected at post-mor-
tem indicated that viral variants had evolved in each of
the three animals[42], most notably in A611 and A613.
The amplification of full-length env ORFs by limiting
dilution PCR has been described previously[42]. In brief,
1 × 106 PBMCs were resuspended in 200 μl phosphate
buffered saline (PBS), and DNA was prepared using
QIAamp DNA blood mini kit (QIAgen Ltd., Crawley,
U.K.) as per manufacturer's instructions. The eluted
DNAs were either used immediately for limiting-dilution
PCR or stored at -80°C. The amplified products were
cloned into either the GL8MYA molecular clone or the
eukaryotic expression vector VR1012 as previous[41]. A
detailed analysis of mutation rates, recombination fre-
quency and quasispecies diversity is described else-
where[42]. In this study we focused on the quasispecies
population from A613 as a preliminary analysis of a ran-
dom selection of nucleic acid sequences obtained by
direct sequencing of the products of the limiting-dilution
PCR which indicated substantial amino acid sequence
diversification. Nucleic acid sequences were ascertained
by using a BigDye® Terminator v1.1 cycle sequencing kit
(Applied Biosystems, Warrington, United Kingdom) and
analysis on an Applied Biosystems 3700 genetic analyser
followed by chromatogram analysis using the Chromas
v1.45 software package (Technelysium Pty. Ltd., Tewan-
tin, Australia).
Characterisation of env genes in vitro
To assess whether the envs encoded functional products,
they were cloned into the GL8MYA molecular clone as
Mlu-I/Nde-I fragments as previous[41] and transfected
into HEK-293T[43,44] cells using SuperFect activated
dendrimer (QIAgen) as per manufacturer's instructions.
Virus was recovered by passage of 0.45 μm-filtered super-
natant onto MYA-1 cells[45], viral growth was then mon-
itored visually for cytopathicity and confirmed by ELISA
for p24. Simultaneously, Envs were subcloned as Sal-I/
Not-I fragments into pVR1012 (Vical Inc., San Diego,
USA) and used to generated HIV(FIV)-luciferase pseudo-
types. 5 μg of each VR1012-env construct and 7.5 μg of
pNL4-3-Luc-E-R-[46] were co-transfected into HEK-
293T cells using SuperFect. The nomenclature
"HIV(FIV)" denotes an FIV Env protein on an HIV parti-
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Envs have been described previously[27,28,37]. Culture
supernatants were collected at 48 hours post-transfec-
tion, filtered at 0.45 μm and frozen at -80°C until
required. Target cell lines were seeded at 5 × 104 cells per
well of a CulturPlate™-96 assay plate (Perkin Elmer, Life
and Analytical Sciences, Beaconsfield, UK) and used
immediately. The cells were then infected with 50 μl of
HIV(FIV) luciferase pseudotypes, cultured for 72 hours
and then luciferase activity quantified by the addition of
50 μl of Steadylite HTS™ (Perkin Elmer) luciferase sub-
strate prior to measurement by single photon counting
on a MicroBeta TriLux luminometer (Perkin Elmer).
Exchange of variable loops in chimaeric GL8 Envs
Variable loops were exchanged between envs in the vec-
tor GL8-414ABSN, a derivative of VR1012-GL8-414[47]
which had been engineered to introduce ApaI, BssHII,
SalI and NheI sites at nucleotides 1000, 1366, 1528 and
1848 respectively (facilitating the exchange of env frag-
ments while reserving the integrity of the amino acid
sequence). The BssHII site was introduced by PCR-
directed mutagenesis using oligonucleotides 7644F 5'-
ACTGAAGCGCGCTTTAGGATT-3' and 7672R 5'-
CTACATCTAATCCTAAAGCGCGCTTC-3' while the
NheI site was introduced with 8118F 5'-GCTATTCAT-
GTTATGCTAGCTCTTG-3' and 8123R 5'-TTGCAA-
GAGCTAGCATAACATGA-3'. Fragments encompassing
the V4 and V5 loops of variants B14, B19 and B28 were
amplified using a high fidelity polymerase chain reaction
and oligonucleotides incorporating flanking 5' BssHII and
3' NheI sites respectively (7644F and 8123R). The prod-
ucts were then purified, digested and cloned into BssHII/
NheI digested GL8-414ABSN. The nucleic acid
sequences of the chimaeric envs were confirmed as above
and then the constructs used to prepare HIV(FIV)
luciferase pseudotypes.
Cells and viruses
MYA-1[45], CLL[27] and MCC[48] cells were cultured in
RPMI 1640 medium; HEK-293T cells were maintained in
Dulbecco's modification of Eagle's medium (DMEM). All
media were supplemented with 10% foetal bovine serum
(FBS), 2 mM glutamine, 0.11 mg/ml sodium pyruvate 100
IU/ml penicillin, 100 μg/ml streptomycin. The medium for
MYA-1 cells was supplemented with conditioned medium
from a murine cell line (L2.3) transfected with a human IL-
2 expression construct (kind gift of M. Hattori, University
of Tokyo, Japan) at a final concentration equivalent to 100
U/ml of recombinant human IL-2, and 50 μM 2-mercapto-
ethanol. All media and supplements were obtained from
Invitrogen Life Technologies Ltd. (Paisley, UK). HEK-293T
cells, and MCC and CLL cells bearing feline CD134 and its
derivatives[27,49] were maintained in media supple-
mented with G418 (InVitrogen, Paisley, UK).
Virus neutralising antibody (VNA) assays
Plasmas were diluted 5-fold in MYA-1 culture medium,
and then 25 μl of each dilution (in triplicate) were incu-
bated with 25 μl of HIV(FIV) luciferase pseudotype, incu-
bated for one hour at 37°C and then added to 50 μl (5 ×
104 cells) of CLL-CD134[27] per well of a CulturPlate™-96
assay plate (Perkin Elmer). The cells were then cultured
for 72 hours and luciferase activity quantified by the addi-
tion of 100 μl of Steadylite HTS™ (Perkin Elmer) luciferase
substrate and measurement by single photon counting on
a MicroBeta luminometer (Perkin Elmer). Percent neu-
tralisation was calculated by comparing the mean
luciferase counts at each plasma dilution with the mean
luciferase counts for the no plasma control.
Inhibition of viral entry
1 × 105 MYA-1 or MCC-CD134 cells were incubated with
either soluble Fc-TNC-CD134L[38] or Fc-CD134[38], or
anti-CD134 (7D6)[39] in complete medium in triplicate
wells of 96-well culture-treated luciferase assay plates
(CulturPlate™ 96) for 30 minutes at 37°C. In assessing
whether pre-incubation with Fc-CD134 enhanced
CD134-independent infection, virus was pre-incubated
with Fc-CD134 for 30 minutes prior to plating on the tar-
get cell line. Viral pseudotypes were then added, and the
plate was returned to the 37°C incubator. Cultures were
maintained for 72 hours post-infection at which point
100 μl of Steadylite HTS™ (Perkin Elmer) luciferase sub-
strate were added and luminescence was measured by
single photon counting on a MicroBeta luminometer
(Perkin Elmer). Percent infection was calculated by com-
paring the mean (n = 3) luciferase activity of each antago-
nist concentration against the mean (n = 3) luciferase
activity of untreated cells (100% infection).
Results
Characterisation of the env quasispecies from A613
The early phase of infection with the GL8 molecular
clone has been described previously[41]; the virus estab-
lished a high proviral load rapidly, and this was main-
tained throughout the duration of the study[41]. Viral
variants cloned from A613 harboured mutations in
regions of Env thought to be associated with tropism and/
or escape from neutralising antibody. It was striking that
even after 322 weeks of infection, 7 species were isolated
with identical amino acid sequences to the infecting
strain GL8 (Fig. 1). Among the variants detected,
hotspots for non-synonymous mutation were identified
at the stem of the V1/V2 loop homologue (L265S, A268D,
N269G and N269K) and the tip of the predicted V5 loop
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Page 4 of 13in SU, and in TM (H648Q, T651A, V655M) (Fig. 2). The
specific targeting of the region adjacent to and including
the predicted N-linked glycosylation site at 269NNT271
was of particular interest as this region had been identi-
fied previously as a determinant of the Env-CD134 inter-
action[49]. The range of substitutions, insertions and
deletions detected in the V5 loop region was remarkable
and suggestive of a strong selective pressure on this
region for evolution, potentially in evasion of the host
immune response. Full length envs encoding intact open
reading frames, and which generated replication-compe-
tent viruses following sub-cloning into the pGL8 MYA
molecular clone and transfection into HEK-293T cells/
recovery into MYA-1 T cells, were subcloned into a
eukaryotic expression vector and used to generate
HIV(FIV) pseudotypes. The receptor usage and neutrali-
sation sensitivity of the variants were then assessed in
vitro. By comparing the distribution of amino acid
sequence changes between the 32 clones, we identified 9
representative env clones that included the majority of
the amino acid changes in Env that would allow us to dis-
tinguish the relative contributions of each variation from
the parent sequence to escape from neutralisation and
altered receptor usage.
Receptor usage of Envs
The GL8 strain of FIV requires determinants in both
CRDs 1 and 2 of its primary receptor CD134 for infec-
tion; chimaeric receptors based on human CD134 and
which express CRD1 only of feline CD134 (feCRD1 chi-
mera) fail to support infection efficiently[27,37]. In con-
trast, strains such as B2542 and PPR use feCRD1
efficiently, suggesting a less stringent, or more flexible
interaction with CD134. We have postulated that this
"simple" interaction may evolve with disease progression,
while the strains that dominate in early infection have a
"complex" high affinity interaction[27,36,37]. The ability
of the A613 variants to utilise native feline CD134 was
compared with the feCRD1 chimera (Fig. 3). The proto-
typic strains with "complex" (GL8) and "simple" (B2542)
interactions displayed high and low dependencies on
CRD2 respectively (ratios of 117 and 5 respectively,
derived by dividing the CPM on feCD134-expressing cells
by the CPM on feCRD1-expressing cells). The variants
isolated from the A613 quasispecies displayed a spectrum
of receptor utilisations, from those similar to the GL8
parent (B23, B31 and B32, ratios of 223, 138 and 112) to
those more similar to B2542 (B14, B28 and B30, ratios of
10, 4 and 11). The amino acid sequences of clones B23, 31
Figure 1 Locations of amino acid sequence mutations in the A613-derived Env clones. Mutations are marked by a red line in either SU (blue) or 
TM (yellow). Positions are shown relative to a linear representation of Env (SU and TM), amino acid numbering is indicated above.
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Page 5 of 13and 32 were identical across V5. The emergence of vari-
ants such as B28 that are able to use the feCRD1 chimera
is consistent with in vivo evolution towards a "simple"
mode of interaction.
Six of the viral variants with distinct Envs were analy-
sed further for sensitivity to antagonists of the virus-
receptor interaction (Fig. 4). Variant B32 was identical to
the parent strain GL8 and therefore served as the refer-
ence strain. If the nature of the virus-receptor interaction
had evolved in vivo, it is likely that this would be reflected
in altered sensitivity to antagonism by anti-CD134 anti-
body (7D6), soluble CD134 (sFc-CD134) or soluble
CD134L (sFc-TNC-CD134L). The six variants displayed a
spectrum of sensitivities to inhibition by 7D6 (Fig. 4A);
B31 and B32 were relatively resistant to inhibition by
7D6, a maximal reduction of ~40% inhibition at 2 μg/ml
while at high concentrations the inhibitory effect disap-
peared (as noted previously for GL8[39]). In stark con-
trast, infection with variants B28 and B14 was reduced by
70% (P = 0.014) and 90% (P = 0.003) respectively at 0.4
μg/ml and blocked completely (>99%) at all concentra-
tions of 2.0 μg/ml or greater (P = 0.0004 at 50 μg/ml).
Thus the mutations acquired by B28 and B14 in vivo had
significantly enhanced sensitivity to antagonism by 7D6.
We next asked whether the viruses differed in their sensi-
tivities to antagonism by soluble CD134 (sFc-CD134)
(Fig. 4B). Infection with B19, B30, B31 and B32 was
blocked with a similar efficiency, a 50-60% reduction in
infectivity being achieved at 2 μg/ml sFc-CD134 and
>95% at the maximum concentration tested (50 μg/ml).
These observations are in marked contrast to pseudo-
types bearing the Envs of variants B14 (P = 0.0003 at 2 μg/
ml) and B28 (P = 0.0002 at 2 μg/ml) which were signifi-
cantly more resistant to antagonism by soluble CD134
(Fig. 4B.), indicating an alteration in the nature of the
virus-receptor interaction following evolution in vivo. It
Figure 2 Schematic structural model of the FIV SU and TM proteins after Pancino et al[67], illustrating the locations of variations in the ami-
no acid sequence of the A613 variants. Mutated amino acids are circled (red) with individual clone numbers indicated. Also shown are potential 
sites for N-linked glycosylation (blue "Y"), di-sulphide bond formation (red line between cysteines) and predicted α-helice formation (grey line).
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Page 6 of 13is noteworthy that the two variants that were most sensi-
tive to inhibition by 7D6 (B14 and B28) were most resis-
tant to antagonism by sFc-CD134.
Previous studies demonstrated that infection with pri-
mary isolates such as GL8 and CPG41 was relatively
resistant to antagonism by soluble CD134L (sFc-TNC-
CD134L) while infection with strains such as B2542 and
PPR was sensitive to modulation[38,39]. sFc-TNC-
CD134L had a modest inhibitory effect on infection with
the six viral variants however most sensitive to inhibition
were B14 and B28 (Fig. 4C, significant reduction at 10 μg/
ml, P = 0.004 and 0.007 respectively), consistent with the
enhanced sensitivity of these two strains to anti-CD134
and reduced sensitivity to soluble CD134.
Previous studies have suggested that pre-incubation of
FIV with soluble Fc-CD134 fusion proteins may facilitate
infection of CXCR4-expressing (CD134-negative)
cells[50,51], the studies indicating that engagement of
Figure 3 Receptor usage of A613 variant Envs. MCC cells stably transduced with retroviral vectors bearing human CD134, a feline CRD1 × human 
CD134 chimaera (feCRD1 chimaera)[27] or feline CD134 were infected with HIV(FIV) luciferase pseudotypes bearing the Envs from variants with dis-
tinct amino acid sequences, in comparison with the GL8 and B2542 Envs. The ratio of luciferase counts on feline CD134 expressing cells divided by 
counts on feCRD1 chimera expressing cells is shown in bold. Each value represents the mean of triplicate estimations +/- standard error and is typical 
of at least two independent experiments.
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Page 7 of 13soluble CD134 triggers a conformational change in the
FIV Env that exposes the CXCR4 binding site[50,51].
Given the low sensitivity of variants B14 and B28 to
antagonism by sFc-CD134 on IL2-dependent (MYA-1) T
cells, we postulated that these variants may partially
escape antagonism by sFc-CD134 by utilising CXCR4 for
infection. To examine this hypothesis, MCC cells stably
transduced with a retroviral vector bearing CD134 (Fig.
4D) or vector only (Fig. 4E) were infected with viral
pseudotypes following pre-treatment with sFc-CD134. As
observed with IL2-dependent T cells (Fig. 4B), sFc-
CD134 blocked infection of MCC-CD134 efficiently with
variants B19, B30, B31 and B32 while variants B14 and
B28 proved more resistant. The sensitivity of the variants
to inhibition was very similar on both MYA-1 and MCC-
CD134 substrates; given that MCC-CD134 express ~100-
fold more surface CD134 than MYA-1 cells[38] the data
suggest that the Env-sFcCD134 interaction itself deter-
mines the degree of inhibition and that within the range
examined, the level of surface CD134 expression on the
target cell does not influence the outcome. When the sFc-
CD134 pre-treated pseudotypes were plated onto control
MCC cells (Fig. 4E), cells that are CD134-negative and
CXCR4-positive[49], we observed no evidence of
enhanced infection by adding increasing concentrations
of sFc-CD134 (values are expressed as percent infection
of control MCC cells compared with MCC-CD134). The
data suggest that pre-incubation of these viruses with
sFc-CD134 does not trigger exposure of the CXCR4-
binding site and mediate CD134-independent infection.
Thus the differential sensitivities of variants B14 and B28,
and variants B19, B30, B31 and B32, to inhibition by sFc-
CD134 and sFc-TNC-CD134L more likely reflects an
intrinsic shift in the nature of the Env-CD134 interaction
with evolution in vivo.
Sensitivity to neutralising antibody
Pressure from the adaptive immune response may drive
the emergence of variants of HIV-1 with novel cell tro-
pisms[52,53] while the growth of viruses in cell culture in
vitro can select for variants with distinct neutralisation
properties[54]. Given that variants had evolved in vivo
with distinct modes of interaction with CD134, we next
asked whether evasion of the humoral immune response
may have provided the driving force for Env evolution.
The sensitivity of nine unique viral variants to neutralisa-
tion by plasma collected post-mortem was assessed in
vitro in comparison with the parent GL8 clone. GL8 and
Figure 4 Sensitivity of A613 Env variants with distinct receptor usages to antagonists of the virus-receptor interaction. HIV(FIV) luciferase 
pseudotypes bearing the B14, B19, B28, B30, B31 and B32 Envs were examined for sensitivity to antagonism by anti-CD134 (A), sFc-CD134 (B, D, E) or 
sFc-TNC-CD134L (C). Infections were performed on MYA-1 cells (A-C), MCC-CD134 (D) or MCC control (E). (E) Pre-incubation with sFc-CD134 did not 
facilitate CD134-independent infection of MCC control cells. Each point represents the mean of triplicate estimations and is expressed as percent in-
fection relative to no antagonist control. Each graph is typical of at least two independent experiments.
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Page 8 of 13the closely related clones B23, 31 and 32 were neutralised
effectively by the P.M. plasma (Fig. 5A). In contrast,
clones B12, B14, B19, B25, B28 and B30 resisted neutrali-
sation by the plasma. The amino acid sequences of the
nine variants were compared with the GL8 clone.
Although no single amino acid substitution correlated
with resistance to neutralising antibody, resistance did
correlate with the acquisition of mutations in V5 per se.
Figure 5 A) Sensitivity of Env variants to neutralisation by homologous plasma from A613. HIV(FIV) luciferase pseudotypes bearing the B12, 
B14, B19, B23, B25, B28, B30, B31, B32 and GL8 Envs were incubated with 1:100, 1:1000, 1:10,000 or 1:100,000 dilutions of A613 plasma and plated onto 
CLL-CD134 cells[27]. Luciferase activity was measured at 72 hours post-infection. Each point represents the mean of triplicate estimations and is ex-
pressed as percent neutralisation relative to the no plasma control. Each graph is typical of at least two independent experiments. B) Neutralising 
activity correlates with variability in the V5 region of Env. Amino acid residues are coloured according to chemical type: basic (dark blue), acidic 
(red), hydrophobic (white), hydroxyl (salmon pink), sulphur-containing (yellow) or amido (lavender blue). Presence or absence of neutralisation is sum-
marised alongside by a green tick or red cross respectively.
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Page 9 of 13While the V5 loops of B23, 31 and 32 were identical to
GL8, those of B12, B14, B19, B25, B28 and B30 bore
amino acid insertions, substitutions or deletions (Fig. 5B).
The data suggest that the V5 region may be a dominant
target for neutralising antibody and that antibodies tar-
geting this region may drive immune escape in FIV infec-
tion.
Exchange of the V5 loop confers resistance to 
neutralisation and modulates the virus-receptor 
interaction
The data suggest that the viral variants derived in vivo
escaped neutralising antibody by the acquisition of muta-
tions in the V5 loop region. We therefore generated chi-
maeric envs in which a fragment encompassing the V4
and V5 loops of the parent 414 strain was exchanged with
the equivalent regions (nts. 1366-1848) of the variants
B14, B19 and B28; HIV(FIV) pseudotypes were prepared
and the sensitivities of the chimaeric Envs to neutralising
antibodies were examined. The mutated GL8 clone ABSN
retained the neutralisation sensitivity of the parent clone
to the A613 plasma, confirming the integrity of the amino
acid sequence post-mutagenesis (Fig. 6). In contrast, sub-
stitution of the V4-V5 domain of ABSN with the corre-
sponding domain of variants B14, B19 or B28 rendered
the virus resistant to neutralisation (Fig. 6). Given that the
only variation in the V4-V5 region between variants B14,
B19 and B28 and the parent clone was the V5 loop itself,
the data are consistent with the dominant neutralising
activity of the PM plasma from A613 targeting V5.
Following exchange of the V4-V5 region of ABSN with
that of the B14, B19 and B28, we assessed the sensitivity
of the chimaeric Env-bearing HIV(FIV) pseudotypes to
antagonists of the virus-receptor interaction (Fig. 7). The
reference GL8 Env (ABSN) conferred low sensitivity to
anti-CD134 (Fig. 7A, 50.9% infection at 2 μg/ml) and high
sensitivity to sCD134 (Fig. 7B, 18.4% infection at 2 μg/ml)
while in contrast, the B14 Env displayed the reverse phe-
notype, an enhanced sensitivity to anti-CD134 (Fig. 7A,
19.5% infection at 2 μg/ml) and reduced sensitivity to
sCD134 (Fig. 7B, 78.2% infection at 2 μg/ml). In compari-
son to the GL8(ABSN) and B14 reference Envs, the
ABSN-B14-V5 chimera acquired the phenotype of the
B14 Env, with high sensitivity to anti-CD134 (Fig. 7A,
6.2% infection at 10 μg/ml, significant increase P = 0.002)
and low sensitivity to sCD134 (Fig. 7B, 65.1% infection at
10 μg/ml, significant reduction P = 0.002). B14 was com-
paratively more sensitive to inhibition by sCD134L (Fig.
7C) however exchange of V5 was insufficient to recapitu-
late this phenotype. The V5 loops of B19 and B28 had
more marginal effects; B28 V5 was similar to that of B14
in that it enhanced sensitivity to anti-CD134 and reduced
sensitivity sCD134; however, the effect was less marked
than that observed with the B14-V5 (as had been
observed with the B28 Env itself earlier (Fig. 4)), suggest-
ing that determinants out with V5 may contribute to the
phenotype of the B28 Env. The sensitivity of the B19 V5
chimera to antagonists of the virus-receptor interaction
did not differ significantly from the GL8 ABSN parent
Env. The data suggest that in the correct context, altera-
tions in the V5 loop that confer resistance to virus neu-
tralisation may modulate substantially the virus-receptor
interaction.
Discussion
In this study, we have demonstrated the evolution of
receptor usage following infection with a homogeneous
preparation of a pathogenic molecular clone of FIV. A
shift in cell tropism with time post-infection has been
described previously for FIV[55,56] and yet the molecular
basis for such a shift has yet to be established. As all
strains of FIV examined to date use CXCR4 as the co-
receptor for infection, an R5 to ×4 shift analogous to that
observed in HIV infection cannot be invoked. Indeed,
while ×4 variants emerge in approximately 50% of HIV-
infected individuals and their detection is often associ-
ated with disease progression [21-23], progression to
AIDS may also occur in the absence of ×4 variants sug-
Figure 6 Conferral of resistance to neutralisation by homologous 
plasma following V5 loop exchange. GL8 Env incorporating non-
coding mutations that introduced restriction enzyme sites facilitating 
V5 loop exchange (GL8 "ABSN") was compared with three chimaeric 
Envs in which the V5s of B14, 19 and 28 had been introduced, or the 
parent B14, B19 and B28 Envs. HIV(FIV) luciferase pseudotypes bearing 
each Env were incubated with 1:10, 1:100, 1:1000, 1:10,000 or 1:100,000 
dilutions of A613 plasma and plated onto CLL-CD134 cells. The chima-
eric Envs bearing the V5s of B14, B19 and B28 recapitulated the neutral-
isation-resistant phenotype of the parent Envs. Each point represents 
the mean (+/- SE) of three replicates and is typical of at least two inde-
pendent experiments.
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Figure 7 Effect of V5 loop exchange upon sensitivity to antagonists of the virus-receptor interaction. HIV(FIV) luciferase pseudotypes bearing 
the GL8 (ABSN) or B14 Envs, or ABSN+V5 loops of B14, 19 and 28 were examined for sensitivity to antagonism by anti-CD134 (A), sFc-CD134 (B) or sFc-
TNC-CD134L (C). Infections were performed on MYA-1 cells. Each point represents the mean of triplicate estimations and is expressed as percent in-
fection relative to no antagonist control. Each graph is typical of at least two independent experiments.
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A B Cgesting that there is not a causal link between the pres-
ence of ×4 variants and the development of AIDS.
Further, the expanded cell tropism of ×4 variants may
come at a cost to the virus in that ×4 variants have been
observed to be targeted more readily by neutralising anti-
bodies and may be kept in check by the humoral immune
response in early infection. Given that determinants of
cell tropism and virus neutralisation may be shared, pres-
sure for escape from neutralising antibodies may drive
alterations in receptor usage and cell tropism[52,53]. In
this study, we present the first evidence for the evolution
of the FIV-CD134 interaction in vivo. The animal exam-
ined in this study was infected with a homogeneous stock
of a molecularly-cloned virus (GL8), a virus known to
induce a decline in CD4+ lymphocytes, achieve a high
viral load and to have a "complex" interaction with
CD134. At post-mortem approximately six years post-
infection, variants were isolated from peripheral blood of
the cat that were resistant to neutralisation by homolo-
gous plasma and which had an altered interaction with
CD134. It is notable that even six years post-infection we
were still able to amplify envs that were identical to the
challenge virus. The diversity of FIV is likely to result
from a combination of the infidelity of reverse tran-
scriptase, inter-variant recombination and the cytidine
deaminase activities of APOBECs, with additional selec-
tive pressure from the host immune response and the
level of receptor and co-receptor expression upon a target
cell population. While the homogeneity of the challenge
virus may have reduced the complexity of the quasispe-
cies observed at post-mortem, we were afforded a unique
opportunity to observe the shift in receptor usage in vivo
that we had predicted in vitro. Why should FIV alter the
way it interacts with CD134? Our studies with antago-
nists of the CD134 interaction suggest that the affinity of
the Env for the primary receptor CD134 may alter as a
consequence of escape from neutralising antibody. Sur-
prisingly, we have uncovered mutations in the highly vari-
able V5 loop of FIV Env that contribute significantly to
the virus receptor interaction.
Sequential isolates of HIV and SIV have demonstrated
the evolution of co-receptor usage in vivo with disease
progression [24,57-61] as predicted by the frequent isola-
tion of CXCR4 variants in symptomatic individuals[21].
Less well-studied are the alterations in the interaction
between lentiviruses and their primary receptor. Intrapa-
tient alterations in the V1V2 and V3 regions of HIV Env
can modulate not only co-receptor usage but also binding
to the primary receptor CD4[62]. Given that FIV uses a
single co-receptor (CXCR4) for infection, the observation
that the interaction between the virus and its primary
receptor evolves in vivo may provide a mechanism
whereby the virus can expand into additional cellular
compartments.
Variants B14 and B28 were able to use CRD1 of feline
CD134, displayed enhanced sensitivity to antagonism by
anti-CD134 antibody or soluble Fc-TNC-CD134L and
were more resistant to inhibition by sFc-CD134, suggest-
ing that the evolution of the virus-receptor interaction
may not simply be a modulation of binding affinity, rather
it could represent a shift in the way the Env and receptor
interact. The two modes of interaction may be considered
as either "complex" (requiring CRD1 and CRD2) or "sim-
ple" (requiring CRD1 only)[36]. It is possible that the
"complex" interaction involves trimeric Env engaging
with trimeric CD134 and is of high affinity while the
"minimal" interaction results from Env binding to either
trimeric or monomeric CD134. Thus the latter pheno-
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Page 11 of 13type of virus would be more sensitive to inhibition by
monomeric/dimeric sFc-CD134. As receptor multimeri-
sation may be promoted by ligand association, or by anti-
CD134 antibody treatment, the viruses engaging in a
complex interaction may selectively target cells exposed
in vivo to soluble CD134L (for example helper T cells in
proximity to CD134L-expressing antigen presenting
cells). In contrast, viruses interacting through CRD1
alone may be suppressed in vivo by endogenously pro-
duced soluble CD134L.
Many of the variants isolated at post-mortem were
resistant to neutralisation by homologous plasma and
each resistant variant harboured mutations in the V5
loop of Env. Exchange of V5 loops between the parent
virus and the late variants confirmed that neutralisation
resistance was afforded by the V5 mutations. A compari-
son of neutralization sensitivities on three different cellu-
lar substrates (MYA-1, MCC-CD134 and CLL-CD134)
gave similar findings (not shown) suggesting that the tar-
geting of V5 was not a vagary of the assay system
employed to measure VNA. The recognition of a linear
peptide from variant B28 by the post-mortem plasma
from A613 (not shown) confirms that the region is immu-
nogenic, however, as we were unable to detect binding of
antibodies within the A613 plasma to linear peptides
derived from the neutralizable parent clone, the epitope
targeted by the VNA is likely to consist of conformational
epitopes encompassing V5. Previous studies have empha-
sised the importance of epitopes within V4 and V5 as tar-
gets for neutralising antibody and the way in which a
single epitope may dominate within polyclonal sera [63-
66]. Understanding the process of immune evasion may
yield valuable insights into the design and optimisation of
candidate vaccine immunogens that induce a protective
immune response.
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